Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF/HFmrEF.
Alwin TubbenGeorge Markousis-MavrogenisLaura M G MeemsBart J van EssenLukas BaumhoveMilou BerendsHendrea Sanne Aletta TingenJohan BijzetBouke P C HazenbergCarolyn S P LamDirk J van VeldhuisenRiemer H J A SlartHans L A NienhuisPeter Van der MeerPublished in: Cardiovascular research (2024)
ATTRwt-CM has a distinctly different biomarker profile compared with HFpEF/HFmrEF, while ATTRwt-CM patients share a similar biomarker profile with AL-CM patients characterized by up-regulation of proteoglycans and cell-adhesion pathways. The biomarkers DCN and IDUA show the potential to serve as an initial screening tool for ATTTRwt-CM. Further research is needed to determine the clinical usefulness of these and other extracellular matrix components in identifying ATTRwt-CM.